The failure of FibroGen, Inc.’s Phase III MATTERHORN trial of roxadustat in anemia among patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) likely seals the drug’s fate in the US market, thereby shifting focus to pamrevlumab, FibroGen’s Phase III candidate for idiopathic pulmonary fibrosis (IPF). But IPF has been a challenging area of development.
FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure
MATTERHORN’s failure did not surprise analysts, but it’s likely the end of the road for roxadustat in the US market. The focus instead has shifted to FibroGen’s IPF asset pamrevlumab.
More from Clinical Trials
More from R&D
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.